KPC(SH:600422) Xin Lang Cai Jing·2025-08-16 02:49Core Viewpoint - Kunming Pharmaceutical Group (600422.SH) reported a decline in both revenue and net profit for the first half of 2025, indicating challenges in its financial performance compared to the previous year [1][3]. Financial Performance - The company's total revenue for the first half of 2025 was 3.351 billion yuan, a decrease of 443 million yuan, representing an 11.68% year-on-year decline [1]. - The net profit attributable to shareholders was 198 million yuan, down by 72.91 million yuan, reflecting a 26.88% decrease compared to the same period last year [1]. - Operating cash flow showed a net inflow of 219 million yuan, which is a reduction of 62.44 million yuan, marking a 22.20% decline year-on-year [1]. Key Financial Ratios - The latest debt-to-asset ratio stood at 46.51%, an increase of 0.51 percentage points from the previous quarter and up 1.74 percentage points from the same period last year [3]. - The gross profit margin was reported at 39.85%, which is an increase of 2.94 percentage points from the previous quarter but a decrease of 1.25 percentage points year-on-year [3]. - Return on equity (ROE) was 3.79%, down by 0.47 percentage points compared to the same period last year [3]. Earnings and Efficiency Metrics - The diluted earnings per share were 0.26 yuan, a decrease of 0.10 yuan, reflecting a 27.78% decline year-on-year [4]. - The total asset turnover ratio was 0.27 times, down by 0.05 times from the previous year, indicating a 16.57% year-on-year decline [4]. - The inventory turnover ratio improved to 1.34 times, an increase of 0.16 times, representing a 13.82% year-on-year rise [4]. Shareholder Structure - The number of shareholders was reported at 39,400, with the top ten shareholders holding a total of 358 million shares, accounting for 47.33% of the total share capital [4]. - The largest shareholder is China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., holding 28.05% of the shares [4].